The introduction of new multi-genotypic direct acting antivirals(DAA) in clinical practice has revolutionized HCV treatment,permitting the achievement of >95% rates of sustainedvirological response in many patients. However, virologicalfailures can occur particularly if the treatments are sub optimaland/or with too short duration. Failure is often associated withdevelopment of resistance. The wide genetic variability in termsof different genotypes and subtypes, together with the naturalpresence and/or easy development of resistance duringtreatment, are intrinsic characteristics of HCV that may affectthe treatment outcome and the chances of achieving avirological cure. This review explores in detail the aspects ofHCV innate and treatment-induced resistance to newinterferon-free DAA regimens.
|Numero di pagine||13|
|Rivista||Current Opinion in Virology|
|Stato di pubblicazione||Published - 2018|
All Science Journal Classification (ASJC) codes